The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
MGMT immunohistochemistry (IHC) and exclusion of pancreatic NET (PanNET) patients from treatment with temozolomide-based therapy.
Diane Lauren Reidy
No relevant relationships to disclose
Olca Basturk
No relevant relationships to disclose
Anuja Kriplani
No relevant relationships to disclose
Ghassan K. Abou-Alfa
No relevant relationships to disclose
William R. Jarnagin
No relevant relationships to disclose
Peter J. Allen
No relevant relationships to disclose
Leonard Saltz
No relevant relationships to disclose
David S. Klimstra
No relevant relationships to disclose
Liying Zhang
No relevant relationships to disclose